{
    "clinical_study": {
        "@rank": "109414", 
        "arm_group": [
            {
                "arm_group_label": "LipiFlow", 
                "arm_group_type": "Experimental", 
                "description": "Single 12-minute LipiFlow treatment"
            }, 
            {
                "arm_group_label": "Untreated Control", 
                "arm_group_type": "No Intervention", 
                "description": "Untreated Control (No Intervention)"
            }, 
            {
                "arm_group_label": "Crossover LipiFlow Treatment", 
                "arm_group_type": "Experimental", 
                "description": "Crossover LipiFlow treatment of the untreated control group after 3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The pilot study objective is to evaluate the potential benefits of LipiFlow\u00ae System\n      treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye\n      by assessing for improvement in meibomian gland function and comfortable contact lens\n      wearing time in comparison to an untreated control."
        }, 
        "brief_title": "Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Meibomian Gland Dysfunction", 
            "Dry Eye"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, non-significant risk, open-label, randomized clinical trial of\n      LipiFlow\u00ae treatment of contact lens wearers with meibomian gland dysfunction and evaporative\n      dry eye.  All subjects undergo examination to determine study eligibility and to capture the\n      Baseline status.   Subjects are randomized to receive LipiFlow\u00ae treatment (Treatment Group)\n      or no LipiFlow\u00ae treatment (Untreated Control Group).  Study endpoints are evaluated at 3\n      Months by comparing the Treatment Group to the Untreated Group.  To facilitate subject\n      recruitment, the Untreated Control group receives Crossover LipiFlow\u00ae treatment (Crossover\n      Treatment Group) at 3 Months.  Both the Treatment and Crossover Treatment groups are also\n      evaluated one month after receiving LipiFlow\u00ae treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of meibomian gland dysfunction and dry eye\n\n          -  At least 18 years of age\n\n          -  Willing to comply with randomization, attend all study visits and follow patient\n             instructions\n\n          -  Habitual soft contact lens wearer 2 to 12 hours/day and 4 to 7 days/week\n\n          -  No change in contact lens type or dimensions for the past 6 months\n\n          -  Reduced comfortable contact lens wearing time\n\n          -  Clinician assessment of acceptable contact lens fit and disinfecting solution\n\n          -  Tear film interferometry of 100 units or less\n\n        Exclusion Criteria:\n\n          -  Systemic disease conditions that cause dry eye\n\n          -  Use of systemic medications known to cause dryness\n\n          -  History of any of the following ocular conditions in the past 3 months: surgery,\n             trauma, Herpes infection, recurrent inflammation, punctal plug insertion or punctal\n             occlusion\n\n          -  Presence of any of the following active conditions: ocular infection, ocular\n             inflammation, moderate to severe allergic conjunctivitis, severe eyelid inflammation,\n             eyelid abnormality that affects lid function, or ocular surface abnormality that\n             compromises corneal integrity\n\n          -  Use of other treatments for meibomian gland dysfunction or dry eye except over the\n             counter lubricants or dietary supplements\n\n          -  Participation in another ophthalmic drug or device trial in the past month\n\n          -  Employee, relative of employee or associate of the clinical site"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102464", 
            "org_study_id": "LF006"
        }, 
        "intervention": {
            "arm_group_label": [
                "LipiFlow", 
                "Crossover LipiFlow Treatment"
            ], 
            "description": "The LipiFlow\u00ae Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.", 
            "intervention_name": "LipiFlow treatment", 
            "intervention_type": "Device", 
            "other_name": "LipiFlow\u00ae Thermal Pulsation System"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Waterloo", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N2L 3G1"
                }, 
                "name": "Centre for Contact Lens Research"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers", 
        "overall_contact": {
            "email": "ccoleman@tearscience.com", 
            "last_name": "Christy Coleman, OD, MPH", 
            "phone": "919-467-4007"
        }, 
        "overall_official": {
            "affiliation": "TearScience, Inc.", 
            "last_name": "Christy Coleman, OD, MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Ethics Review Committee", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change in Meibomian Gland Score from Baseline", 
            "safety_issue": "No", 
            "time_frame": "3 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102464"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Questionnaire", 
            "measure": "Mean change in comfortable contact lens wearing time from Baseline", 
            "safety_issue": "No", 
            "time_frame": "3 Months"
        }, 
        "source": "TearScience, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TearScience, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}